Table 3. Phase III trials of combination with platinum-based CT and EGFR TKI in 1st-line.

Trial	Study population	Treatment	No. of pts	Median OS	RR (%)	P
INTACT 1	Treatment naive	Cis/gem + gefitinib 500	1,093	9.9 months	50
		Cis/gem + gefitinib 250		9.9 months	51	NS
		Cis/gem + placebo		10.9 months	47
INTACT 2	Treatment naive	Carbo/pacli + gefitinib 500	1,037	8.7 months	30
		Carbo/pacli + gefitinib 250		9.8 months	30	NS
		Carbo/pacli + placebo		9.9 months	29
TRIBUTE	Treatment naive	Carbo/pacli + erlotinib 150	1,079	10.6 months	22	NS
		Carbo/pacli + placebo		10.5 months	19
TALENT	Treatment naive	Cis/gem + erlotinib 150	1,172	43 weeks	32	NS
		Cis/gem + placebo		44.1 weeks	30

NS, not significant; EGFR, epidermal growth factor receptor; TKI, tyrosine-kinase inhibitor; RR, response rates.